COVID-19 therapy with anti-COVID-19 antibodies in convalescent serum Question: 3/26/2020 The cancer patients with Non-Hodgkins Lymphoma who have had CAR-T therapy are receiving IVIG since they are enabled to make antibodies following this therapy. What treatments are available for these patients or other patient with hypogammaglobulinemia that show severe signs of COVID-19 infection? Presumable no IVIG product presently conveys any passive antibodies to this virus. Would plasma have specific COVID-19 protective anti-viral antibodies? Hydrochloroquine and azithromycin are in short supply in Northern New Jersey even though it has no proven role in treating this virus to date. Answer: COVID-19 therapy with anti-COVID-19 antibodies in convalescent serum can be studied with FDA approval under a single patient emergency IND. https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/investigational-covid-19-convalescent-plasma-emergency-inds Here is a background article: https://www.jci.org/articles/view/138003 Eric Macy, MD, MS, FAAAAI